ZUP1 and cancer: This is best highlighted by the fact that PRC2 and PR-DUB have both gain- and loss-of-function mutations in different cancer contexts (Morin et al., 2010; Ntziachristos et al., 2012; Balasubramani et al., 2015; Conway et al., 2021).